RecruitingPsoriasis Vulgaris
Psoriatic Immune Response to Tildrakizumab
Eligible age
18–75 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Sponsor: University of California, San Francisco
You may qualify if…
- ✓ 18 years of age or older
- ✓ Patients with moderate-severe psoriasis or \> 5% body surface area affected.
You may not qualify if…
- ✕ taking systemic immunosuppressives in the last 4 weeks
- ✕ pregnancy
- ✕ severe immunodeficiency (either from genetic or infectious causes).
- ✕ tuberculosis or other active serious infection
- ✕ active systemic malignancy.
- ✕ breast-feeding
- ✕ Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Where it's recruiting
California
San Francisco
Source: ClinicalTrials.gov · NCT05390515 · last updated 2026-06-04